info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
27
Jul
CymaBay Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
15
Jul
CymaBay Therapeutics Announces Pricing of $20 Million Public Offering of Common Stock
14
Jul
CymaBay Announces Proposed Public Offering of Common Stock
6
Jul
CymaBay Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
12
Jun
CymaBay Therapeutics Presents Poster at EULAR 2015
29
May
CymaBay to Present at the Jefferies 2015 Global Healthcare Conference
15
May
CymaBay to Present at the 2015 UBS Global Healthcare Conference
7
May
CymaBay Reports First Quarter 2015 Financial Results
1
May
CymaBay to Announce First Quarter 2015 Financial Results on Thursday, May 7, 2015
23
Apr
CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia
<< Previous
1
2
3
4
Next >>
Show All
Scroll
